San Diego, CA — Binding Site’s Immunologicals Group is pleased to announce the addition of a new, purified monoclonal antibody to be used for the analysis and testing of the Rubella. This novel monoclonal antibody, the Rubella MAb R22T, has been expressly designed for use as integral component within enzyme immunoassay (EIA) test procedures and is certain to benefit the needs of clinical, biopharmaceutical, and life science researchers, as well as manufacturers of in-vitro diagnostic (IVD) test kits.
Credit: Binding SiteRubella, also known as German measles, is an infection caused by the Rubella Virus. This disease is often mild, with half of people not even realizing that they are infected. However, infection during early pregnancy may result in a child born with congenital rubella syndrome (CRS), or miscarriage. Symptoms of CRS also include problems with the eyes, such as cataracts; the ears, such as deafness; the heart; and the brain.
This monoclonal antibody is sourced from mice and manufactured to a purity level of > 95 percent, while displaying exceptional sensitivity and specificity. In addition, the antibody offers excellent lot-to-lot consistencies and features an outstanding shelf-life claim of four years from the date of manufacture. It is supplied preservative-free and comes packaged in ergonomically designed 1.0mg filled vials, with larger, bulk packaging configurations also available.
Binding Site’s Immunologicals Group serves the in-vitro diagnostic (IVD) manufacturing and biopharmaceutical | clinical | life-science | medical research markets with a comprehensive line of innovative products. For additional information, contact The Binding Site, Inc. at 6730 Mesa Ridge Road, San Diego, CA 92121 USA. Phone: 800-633-4484; FAX: 858-453-9189; Email: email@example.com. Please visit our website at www.immunologicals.com.